Engflag

Drizalma Sprinkle

Quick links to important sections

Drizalma Sprinkle

There is no image.

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Drizalma Sprinkle

What is Drizalma Sprinkle? (Overview)

Property Description
Active Ingredient Duloxetine hydrochloride
Pharmacological Class Selective Serotonin and Norepinephrine Reuptake Inhibitor (SNRI)
Form Delayed-release capsule containing pellets (Sprinkle formulation)
Route Oral administration
Origin Synthetic chemical compound

Drizalma Sprinkle: Identity and Pharmacological Classification

Drizalma Sprinkle is a synthetic, single-ingredient, prescription medicine that contains the active compound Duloxetine hydrochloride. It is formally classified as a Selective Serotonin and Norepinephrine Reuptake Inhibitor (SNRI). This classification places it among medications designed to modulate chemical signaling in the central nervous system. Pharmacological studies confirm this drug's recognized role in the rebalancing of neurotransmitter levels. The mechanism of action involves the dual inhibition of the reuptake of two key chemical messengers, serotonin and norepinephrine, which is the foundational principle for its general therapeutic role in managing mood and chronic pain signals. The dual mechanism of action helps stabilize emotional states and may improve the body's processing of persistent, long-term discomfort, making the substance clinically recognized for its broad utility.

Composition and Unique Delayed-Release Form

The drug is formulated for oral administration as a specialized delayed-release capsule that holds numerous tiny, enteric-coated pellets. This composition is critical because the Duloxetine is highly susceptible to degradation by stomach acids, and the specialized coating ensures its safe passage and controlled release later in the intestinal tract. The designation of "Sprinkle" reflects the key differentiating factor of this product: the capsule may be swallowed whole or, for individuals with difficulty swallowing—a patient group that includes certain pediatric patients and adults—the capsule can be opened to sprinkle the pellets onto a small amount of soft food. This specific formulation provides an important option for patients who require an alternative to conventional solid-swallow oral medications while maintaining the necessary delayed-release properties of the active ingredient.

What side effects are possible with Drizalma Sprinkle?

Possible Side Effects and Safety Information

The safety profile of Drizalma Sprinkle, which contains Duloxetine hydrochloride, is officially categorized by government regulatory bodies based on the frequency and type of documented adverse reactions. These effects are generally classified by the System-Organ Class (SOC) affected, such as the nervous system or gastrointestinal tract.

Regulatory Classification of Adverse Reactions

Very Common reactions (occurring in 1 out of 10 people or more) typically include nausea, headache, and dry mouth. Common reactions (occurring in 1 out of 100 to less than 1 out of 10 people) often involve dizziness, somnolence (drowsiness), insomnia, constipation, and hyperhidrosis (excessive sweating).

Serious Adverse Reactions and Safety Constraints

Official labels highlight the documentation of serious adverse reactions, which are typically rare but clinically significant. These include Serotonin Syndrome, Hepatotoxicity (severe liver injury), and a documented increased risk of suicidal thinking and behavior, particularly in adolescents and young adults, especially at the start of therapy or following dose changes. Safety constraints define that the medication is contraindicated in individuals with severe hepatic impairment and uncontrolled narrow-angle glaucoma.

Time- and Population-Specific Safety Notes

Regulatory safety information notes that many adverse effects, such as nausea and dizziness, are more frequently observed during treatment initiation and dose escalation. Specific safety considerations exist for certain populations: Older adults may have an increased risk of falls and hyponatremia. In pediatric and adolescent patients, there is an increased risk of suicidal ideation and the need for growth monitoring. Discontinuation syndrome (withdrawal effects) is documented upon abrupt cessation of treatment.

Overdose and Emergency Response

Overdose and When to Seek Help: Official Regulatory Information

Overdose Symptoms and Manifestations

Official regulatory sources document a range of clinical signs associated with Drizalma Sprinkle (duloxetine) overdose. These documented presentations include somnolence, dizziness, vomiting, and changes in blood pressure (both hypertension and hypotension). More serious and life-threatening outcomes have been reported, such as seizures, coma, and the development of Serotonin Syndrome. Serotonin Syndrome can involve agitation, hallucinations, muscle rigidity, fever, and a fast or irregular heartbeat. Fatal outcomes have been reported with acute overdoses, particularly when other drugs are co-ingested.

Emergency Actions and Supportive Care

The regulatory guidance is explicit that there is no specific antidote available to reverse the effects of duloxetine overdose. Management must therefore be entirely supportive and symptomatic. Required procedural steps include establishing a clear and maintained airway, ensuring adequate oxygenation and ventilation, and continuous monitoring of the patient's vital signs and cardiac rhythm.

When Immediate Medical Help is Required

Patients or caregivers must seek emergency medical attention immediately upon suspicion of overdose. According to official labeling, urgent assistance is mandatory if the affected person has collapsed, had a seizure, is experiencing trouble breathing, or cannot be awakened. Contacting emergency services or a certified Poison Control center is required in all suspected overdose situations.

Therapeutic Uses of Drizalma Sprinkle

What Drizalma Sprinkle Treats: Main Uses and Benefits

Drizalma Sprinkle is a therapeutic agent generally used for the long-term management of several chronic conditions across neuropsychiatric and pain domains. Clinical application often focuses on settings marked by heightened patient distress and functional impairment, providing supportive symptomatic relief.

The medication is applied across three primary symptom categories: managing persistent mood disturbances and excessive worry (associated with Major Depressive Disorder and Generalized Anxiety Disorder); easing long-term nerve-related pain (Diabetic Peripheral Neuropathic Pain); and providing support for widespread musculoskeletal discomfort (including Fibromyalgia, chronic lower back pain, and pain due to osteoarthritis). It is relevant in contexts where symptoms create noticeable functional strain and where additional management of discomfort is required.

“This therapy helps address symptom clusters that may become intense or disruptive, offering supportive relief that contributes to functional stability.”

The use of this medication assists with functional stability by easing the overall symptom burden, helping patients cope more steadily with these long-term emotional and physical challenges.

Quick Fact: Relief for Chronic Pain The therapy is considered relevant for managing pain symptoms that are persistent and long-standing, especially those categorized as neuropathic (e.g., burning, shooting) or widespread musculoskeletal discomfort.

Regulatory References

  1. NIH DailyMed Label for Duloxetine

Eligibility and Restrictions for Use

The eligibility profile for Drizalma Sprinkle is defined by specific prohibitions and age-based limitations detailed in regulatory documents.

Contraindicated Populations

The medicine is contraindicated for patient groups using Monoamine Oxidase Inhibitors (MAOIs), linezolid, or intravenous methylene blue. Use is also strictly prohibited in patients with pre-existing conditions such as chronic liver disease, substantial alcohol use, uncontrolled hypertension, and uncontrolled narrow-angle glaucoma.

Organ Function and Age Restrictions

Organ function status is a major limitation. Regulatory labeling advises to avoid use in patients with any degree of hepatic impairment and those with severe renal impairment (Glomerular Filtration Rate (GFR) less than 30 mL/minute).

For age-based use, the medicine is approved for adults for all official uses. Pediatric eligibility is restricted: use is established for Generalized Anxiety Disorder (GAD) in patients 7 years and older, and for Fibromyalgia in adolescents 13 years and older. Safety and effectiveness are not established for any indication in children under 7. Caution is recommended for geriatric patients and those with a history of seizure or bipolar disorders.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Drizalma Sprinkle (duloxetine) can interact with several other medicines and substance classes, potentially leading to serious or clinically significant effects. It is contraindicated for use with Monoamine Oxidase Inhibitors (MAOIs), including the psychiatric MAOIs isocarboxazid, phenelzine, and tranylcypromine, as well as linezolid and intravenous methylene blue. This combination poses a high risk for Serotonin Syndrome, a potentially life-threatening condition. A washout period is required: Drizalma Sprinkle must not be started within 14 days of stopping an MAOI, and an MAOI must not be started within 5 days of stopping Drizalma Sprinkle.

Co-administration with other serotonergic agents—such as SSRIs, SNRIs, tricyclic antidepressants, triptans, fentanyl, lithium, and tramadol—also increases the risk of Serotonin Syndrome and requires careful monitoring.

Duloxetine may increase the risk of bleeding events. Therefore, caution is advised when co-administering Drizalma Sprinkle with antiplatelet drugs (e.g., aspirin), Nonsteroidal Anti-inflammatory Drugs (NSAIDs), or anticoagulants (e.g., warfarin).

The drug is metabolized by liver enzymes, primarily CYP1A2 and CYP2D6. The concomitant use of potent CYP1A2 inhibitors (e.g., thioridazine) is generally to be avoided, as it can significantly increase duloxetine blood levels. Duloxetine itself is a moderate inhibitor of CYP2D6, and dose reduction for drugs primarily metabolized by this enzyme may be necessary when they are used together.

Mechanism of Action

The mechanism of Drizalma Sprinkle involves the modulation of two key neurotransmitter pathways in the Central Nervous System (CNS), primarily affecting signal intensity and duration.

Dual Neurotransmitter Signal Amplification

The drug acts as a dual inhibitor of both the Serotonin Transporter ( SERT) and the Norepinephrine Transporter ( NET). By binding to these proteins on nerve cells, Drizalma Sprinkle blocks the reabsorption of the neurotransmitters serotonin ( 5-HT) and norepinephrine ( NE) from the synaptic space. This mechanism increases the concentration and prolongs the duration of activity of these two chemical messengers on their respective postsynaptic receptors.

Modulation of Central Inhibitory Pathways

The resulting sustained elevation of NE and 5-HT occurs within the descending inhibitory pathways that travel from the brainstem to the spinal cord. Activation of alpha2-adrenergic and serotonergic receptors within the spinal cord modulates this endogenous system. This action suppresses the transmission of afferent nociceptive signals. The final physiological consequence is the modulation of central processing and filtering of persistent signal input.

Dosage and Administration Information

How to Use Drizalma Sprinkle: Administration Guidelines

Administration of Drizalma Sprinkle is strictly by the oral route. The medication is a delayed-release capsule containing enteric-coated pellets, which must not be crushed or chewed to preserve the active ingredient's absorption properties. The capsule may be swallowed whole, but a unique administration option allows the capsule to be opened and the entire contents sprinkled onto one tablespoon of applesauce. This pellet-applesauce mixture must be consumed immediately and is not intended for storage.

Standard Dosing and Frequency

Therapy is typically initiated using a titration schedule before reaching the target maintenance dose. The general frequency is once daily or twice daily depending on the specific approved use. The medication may be taken with or without food.

Indication Starting Dose Maintenance Dose Maximum Daily Dose
MDD / GAD 30 mg once daily for 1 week 60 mg once daily 120 mg/day
DPNP / FM / CMP 30 mg once daily for 1 week 60 mg once daily 60 mg/day

Population and Missed Doses

Specific dosage adjustments apply to certain patient groups. For geriatric patients and pediatric patients (ages 7 to 17) with Generalized Anxiety Disorder (GAD), initiation typically begins with 30 mg once daily for two weeks before the dose is increased. If a dose is missed, the standard protocol is to take the dose as soon as remembered, unless it is almost time for the next scheduled dose, in which case the missed dose should be skipped. When discontinuing the medication, the dose must be gradually reduced rather than stopped abruptly.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Drizalma Sprinkle

Evidence Landscape for Major Depressive Disorder (MDD)

Research exploring MDD primarily consists of short-term, randomized, placebo-controlled trials in adults, typically lasting 6 to 16 weeks. Researchers examined specific outcomes related to symptom intensity and also examined outcomes reflecting daily functioning or activity level. Short-term findings describe patterns observed in the studies related to symptom intensity or variability. However, systematic reviews note that some reviews describe the measured change as having a small to moderate magnitude, and the clinical importance of these reported changes remains a point of uncertainty for some patients. Independent reviews also indicate that the existing trials often carry a noted risk of bias.

Evidence Landscape for Generalized Anxiety Disorder (GAD)

The research exploring Generalized Anxiety Disorder was evaluated in a series of short-term controlled trials, typically spanning nine to fifteen weeks. The studies explored how symptoms related to both psychic (mental) and somatic (physical) manifestations change. The evidence contributes to the broader understanding of short-term symptom patterns in this condition, with findings generally reporting how symptoms evolved in the observed adult populations.

Evidence Landscape for Chronic Pain Conditions

This medicine was studied for conditions involving periods of heightened symptoms such as pain associated with diabetic peripheral neuropathy (DPNP) and chronic musculoskeletal pain (e.g., Fibromyalgia, Low Back Pain, Osteoarthritis). These studies were mainly short-term, lasting 10 to 13 weeks. Researchers explored outcomes related to physical discomfort and daily functioning or activity level. For chronic pain, systematic reviews indicate that the measured change compared to placebo is often described as having a small to moderate magnitude.

Research Gaps and Areas of Uncertainty

The research provides context but not individual predictions, and findings describe group patterns, not personal outcomes. A significant limitation is that the follow-up durations were limited. The long-term effects are not fully established, and data for long-term outcomes for chronic pain management remain insufficient beyond the trial periods. Furthermore, trials conducted for pediatric MDD were observed in some studies to be inconclusive, as primary symptom measures did not consistently report differences between the drug and placebo.

Key Studies & References A Systematic Review of Efficacy, Safety, and Tolerability of Duloxetine - Frontiers in Psychiatry

Frequently Asked Questions (FAQ)

Common questions about Drizalma Sprinkle (FAQ)

Q: What is Drizalma Sprinkle used for?

According to the official product information, Drizalma Sprinkle is approved to treat specific conditions. These include Major Depressive Disorder (MDD) in adults, Generalized Anxiety Disorder (GAD) in adults and children 7 years and older, and Diabetic Peripheral Neuropathic Pain (DPNP) in adults.

Q: How does Drizalma Sprinkle work in the body?

Regulatory documents state that Drizalma Sprinkle is a type of medicine called a Serotonin and Norepinephrine Reuptake Inhibitor (SNRI). It is thought to work by increasing the amounts of the chemical messengers serotonin and norepinephrine in the brain. This activity helps improve mood and reduce pain signals in the body.

Q: Is Drizalma Sprinkle available in different strengths?

Yes, official product information indicates that Drizalma Sprinkle is available in a range of strengths. The medication comes as delayed-release capsules containing duloxetine hydrochloride. These strengths are available to support the dosage prescribed by a healthcare provider.

Q: Is Drizalma Sprinkle the same as Cymbalta?

Regulatory documents state that Drizalma Sprinkle contains the active ingredient duloxetine hydrochloride. This is the same active ingredient found in the brand-name medicine Cymbalta. Drizalma Sprinkle is formulated as a delayed-release capsule.

Q: What should I do if I miss a dose of Drizalma Sprinkle?

The official product information contains specific instructions for missed doses. Generally, patients are advised to follow their regular schedule if it is nearly time for the next dose, and to avoid doubling up. Consult the official Patient Information Leaflet or your prescriber for detailed guidance.

Q: Can I open the Drizalma Sprinkle capsule and sprinkle the contents on food?

Official information indicates that Drizalma Sprinkle capsules may be opened, and the contents—the medicated beads—can be sprinkled over a small amount of applesauce. The official product instructions specify that if the capsule is opened, the beads must be swallowed without chewing, and consumed right away.

Q: How long does it take for Drizalma Sprinkle to start working?

Studies and official information suggest that some people may begin to notice an improvement in their symptoms within 1 to 2 weeks of starting treatment. However, the full benefit for depression, anxiety, or nerve pain may take 4 weeks or longer to be fully realized.

How should Drizalma Sprinkle be stored and disposed of?

How to Store and Dispose of Drizalma Sprinkle?

Drizalma Sprinkle must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with permitted excursions. Keep the medication in its original container with the cap tightly closed and store it away from excess heat and moisture. Do not freeze the product.

Handling and Stability

If the capsule is opened and its contents mixed with food, the prepared dose must be swallowed immediately and not stored for later use. The delayed-release pellets must not be crushed or chewed.

Disposal and Child Safety

Keep Drizalma Sprinkle out of the sight and reach of children and pets. Unused or expired medication should be discarded using an authorized drug take-back program. Do not flush the capsules down a toilet or pour them down a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Drizalma Sprinkle found in:

A-Z Index: